To improve ICB-immunotherapy, targeting angiogenesis such as anti-VEGF, which was considered to inhibit the sprouting of new vessels and also “normalize” the tumor vasculature to improve immune cell infiltration, was combined with anti-PD-1/PD-L1 for the cancer treatment and obtained efficacious effects in HCC treatment [23, 25, 41]. Here, VEGFA is linked to cancer.